BR112018003741A2 - composições biofarmacêuticas - Google Patents

composições biofarmacêuticas

Info

Publication number
BR112018003741A2
BR112018003741A2 BR112018003741A BR112018003741A BR112018003741A2 BR 112018003741 A2 BR112018003741 A2 BR 112018003741A2 BR 112018003741 A BR112018003741 A BR 112018003741A BR 112018003741 A BR112018003741 A BR 112018003741A BR 112018003741 A2 BR112018003741 A2 BR 112018003741A2
Authority
BR
Brazil
Prior art keywords
compositions
biopharmaceutical compositions
biopharmaceutical
present disclosure
disclosure relates
Prior art date
Application number
BR112018003741A
Other languages
English (en)
Inventor
Dally Jennifer
Spatara Michelle
A Monck Myrna
B Bam Narendra
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018003741(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112018003741A2 publication Critical patent/BR112018003741A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente divulgação refere-se às composições para tratar doenças mediadas por interleucina 5 (il-5) e métodos relacionados.
BR112018003741A 2015-08-24 2016-08-22 composições biofarmacêuticas BR112018003741A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02
PCT/IB2016/055012 WO2017033121A1 (en) 2015-08-24 2016-08-22 Biopharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112018003741A2 true BR112018003741A2 (pt) 2018-09-25

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003741A BR112018003741A2 (pt) 2015-08-24 2016-08-22 composições biofarmacêuticas

Country Status (22)

Country Link
US (7) US10870695B2 (pt)
EP (2) EP3341409A1 (pt)
JP (3) JP6821659B2 (pt)
KR (1) KR20180037275A (pt)
CN (5) CN116327921A (pt)
AU (1) AU2016311385C1 (pt)
BR (1) BR112018003741A2 (pt)
CA (1) CA2996088A1 (pt)
CL (1) CL2018000499A1 (pt)
CO (1) CO2018001840A2 (pt)
CR (1) CR20180115A (pt)
DO (1) DOP2018000057A (pt)
EA (1) EA037487B1 (pt)
IL (1) IL257539A (pt)
MA (1) MA42692A (pt)
MX (1) MX2018002319A (pt)
PE (1) PE20181176A1 (pt)
PH (1) PH12018500379A1 (pt)
TW (2) TWI750133B (pt)
UY (1) UY36868A (pt)
WO (1) WO2017033121A1 (pt)
ZA (1) ZA201801158B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327921A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MX2019007642A (es) 2016-12-23 2019-09-09 Cephalon Inc Anticuerpos anti-il-5.
EP3630824A1 (en) * 2017-05-26 2020-04-08 GlaxoSmithKline Intellectual Property Development Ltd Biopharmaceutical compositions and related methods
CA3064859A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
TWI801425B (zh) * 2017-09-29 2023-05-11 大陸商江蘇恆瑞醫藥股份有限公司 Il-5 抗體、其抗原結合片段及醫藥用途
WO2019224724A1 (en) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions comprising antibody variants
JP2022528230A (ja) * 2019-03-29 2022-06-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
US20230059341A1 (en) * 2019-12-18 2023-02-23 Tesaro, Inc. Biopharmaceutical compositions and related methods
CA3232203A1 (en) * 2021-09-22 2023-03-30 James MATTHAEI Il5ra cell surface markers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
WO1996021000A2 (en) 1994-12-23 1996-07-11 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP5528710B2 (ja) 2006-02-28 2014-06-25 オリガシス コーポレイション アクリロイルオキシエチルホスホリルコリン含有ポリマー抱合体及びその製法
WO2008134724A2 (en) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2274009B1 (en) 2008-03-28 2013-11-13 GlaxoSmithKline LLC Methods of treatment
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CN102711756A (zh) 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
ES2791690T3 (es) 2011-02-09 2020-11-05 Glaxosmithkline Llc Formulaciones liofilizadas
KR20140018966A (ko) * 2011-04-07 2014-02-13 글락소스미스클라인 엘엘씨 점도가 감소된 제제
JP2014510152A (ja) 2011-04-07 2014-04-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 粘度が低減された処方物
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG11201504260UA (en) * 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
WO2014141149A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
EP3052092A2 (en) 2013-10-02 2016-08-10 Vectura Limited Method and apparatus
BR112016017248A8 (pt) 2014-01-24 2018-04-17 Ngm Biopharmaceuticals Inc anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos
CN106536551B (zh) 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
CN116327921A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物

Also Published As

Publication number Publication date
US20210332125A1 (en) 2021-10-28
PE20181176A1 (es) 2018-07-20
TW202233238A (zh) 2022-09-01
JP2022023049A (ja) 2022-02-07
US20180251539A1 (en) 2018-09-06
US11299541B2 (en) 2022-04-12
CN116327922A (zh) 2023-06-27
AU2016311385B2 (en) 2019-05-09
ZA201801158B (en) 2019-08-28
CN108137683A (zh) 2018-06-08
US20220380452A1 (en) 2022-12-01
TWI750133B (zh) 2021-12-21
US10870695B2 (en) 2020-12-22
UY36868A (es) 2017-03-31
AU2016311385C1 (en) 2019-08-22
US20220185878A1 (en) 2022-06-16
DOP2018000057A (es) 2018-03-15
CN116474091A (zh) 2023-07-25
EA037487B1 (ru) 2021-04-02
EP3341409A1 (en) 2018-07-04
TWI780988B (zh) 2022-10-11
JP7463070B2 (ja) 2024-04-08
JP2018526369A (ja) 2018-09-13
JP6821659B2 (ja) 2021-01-27
US20210340247A1 (en) 2021-11-04
TW201722473A (zh) 2017-07-01
JP2020033351A (ja) 2020-03-05
KR20180037275A (ko) 2018-04-11
US11274148B2 (en) 2022-03-15
WO2017033121A1 (en) 2017-03-02
CA2996088A1 (en) 2017-03-02
EA201890572A1 (ru) 2018-10-31
CN116327923A (zh) 2023-06-27
CO2018001840A2 (es) 2018-05-31
AU2016311385A1 (en) 2018-03-15
CR20180115A (es) 2018-04-12
US11286298B2 (en) 2022-03-29
IL257539A (en) 2018-04-30
MX2018002319A (es) 2018-04-11
US20200199219A1 (en) 2020-06-25
CL2018000499A1 (es) 2018-07-06
MA42692A (fr) 2018-07-04
PH12018500379A1 (en) 2018-09-03
US20210340246A1 (en) 2021-11-04
EP4056590A1 (en) 2022-09-14
US11459384B2 (en) 2022-10-04
CN116327921A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
BR112018003741A2 (pt) composições biofarmacêuticas
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018009706A2 (pt) composições compreendendo cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
BR112019012342A2 (pt) anticorpos il-11
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112017024123A2 (pt) construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica
EA201691582A1 (ru) Новые фармацевтические препараты
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
CO2017001212A2 (es) Moléculas que tienen ciertas utilidades pesticidas y productos intermediarios, composiciones y procesos relacionados con las mismas
BR112017013498A2 (pt) composições de inibidor de nitrificação e métodos para a preparação das mesmas
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
CL2017000312A1 (es) Elección de microarn como diana para trastornos metabólicos
BR112016030129A2 (pt) Composição, artigo moldado por injeção e processo para produzir um artigo moldado por injeção
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]